GlassScriptPhysician profile
Chris Wayne Crawford
NPI 1447248281
$15,681.08
in general payments reported to CMS, 2019-2025
42 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $1,216 · 2021: $1,160 · 2022: $2,476 · 2023: $2,820 · 2024: $3,379 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,236 · Education: $26.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,236.41 |
| Education | $26.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,275.79 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Regeneron Healthcare Solutions, INC. | $1,380.33 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,003.16 | 2019-2025 | |
| Janssen Biotech, INC. | $991.64 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $949.47 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $822.89 | 2023-2025 | Zoryve |
| Incyte Corporation | $741.49 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $712.83 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Leo Pharma INC. | $700.18 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $651.50 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Dermavant Sciences, INC. | $571.37 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $567.20 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $525.31 | 2019-2025 | |
| Amgen INC. | $482.26 | 2020-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $424.97 | 2019-2025 | Cabtreo, Jublia, Arazlo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $413.71 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $353.64 | 2019-2024 | |
| Almirall LLC | $310.50 | 2019-2025 | Seysara, Klisyri |
| Allergan, INC. | $308.33 | 2019-2022 | |
| Ucb, INC. | $185.84 | 2019-2024 | Bimzelx |
| Lumenis Be INC | $144.46 | 2022 | |
| Encore Dermatology INC. | $143.66 | 2019-2020 | |
| Epi Health, LLC | $137.20 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $135.43 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $115.83 | 2022-2024 | Sotyktu |
| Nabriva Therapeutics, Plc | $108.66 | 2021-2022 | |
| Journey Medical Corporation | $67.64 | 2019-2025 | |
| Organon LLC | $57.71 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.21 | 2023-2024 | Cyltezo, Spevigo |
| Dermira, INC. | $50.45 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $41.63 | 2019 | |
| Celgene Corporation | $38.31 | 2019 | |
| Aclaris Therapeutics, INC. | $34.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $32.44 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $28.76 | 2024 | Ycanth |
| Medimetriks Pharmaceuticals, INC. | $26.53 | 2023 | |
| Biofrontera INC. | $19.12 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Kyowa Kirin, INC. | $15.59 | 2023 | Poteligeo |
| Krystal Biotech INC | $15.53 | 2024 | Vyjuvek |
| Teva Pharmaceuticals USA, INC. | $14.18 | 2023 | Austedo |
| Promius Pharma LLC | $13.23 | 2019 | |
| Sandoz INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.